Opioid use disorder in pregnancy

Obstetrics and Gynecology

Volumn 128, Issue 1, 2016, Pages 4-10

  Krans, Elizabeth E ^a   Patrick, Stephen W ^a  

^a UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

OPIATE;

ARTICLE; EPIDEMIC; EVIDENCE BASED PRACTICE; FEMALE; HEALTH CARE ACCESS; HEALTH CARE AVAILABILITY; HEALTH CARE PERSONNEL; HEALTH CARE POLICY; HIGH RISK PATIENT; HUMAN; OPIATE ADDICTION; OUTCOME ASSESSMENT; PATIENT CARE; PATIENT SAFETY; PREGNANCY; PREGNANT WOMAN; PRENATAL CARE; PRESCRIPTION; PRIORITY JOURNAL; RISK REDUCTION; SUBSTANCE USE; WITHDRAWAL SYNDROME; COMPLICATION; LEGISLATION AND JURISPRUDENCE; NEONATAL ABSTINENCE SYNDROME; NEWBORN; OPIOID-RELATED DISORDERS; ORGANIZATION AND MANAGEMENT; PERINATAL CARE; PREGNANCY COMPLICATIONS; PROCEDURES; STANDARDS; TOTAL QUALITY MANAGEMENT; TRENDS;

FEMALE; HEALTH POLICY; HUMANS; INFANT, NEWBORN; NEONATAL ABSTINENCE SYNDROME; OPIOID-RELATED DISORDERS; PERINATAL CARE; PREGNANCY; PREGNANCY COMPLICATIONS; QUALITY IMPROVEMENT;

EID: 84973277697     PISSN: 00297844     EISSN: 1873233X     Source Type: Journal    
DOI: 10.1097/AOG.0000000000001446     Document Type: Article

References (44)

1. National Drug Control Strategy. Data supplement 2014. Available at: https://www.whitehouse.gov/sites/default/files/ondcp/policy-And-research/ndcs-data-supplement-2014.pdf. Retrieved January 7, 2016.
2. Krans EE, Zickmund SL, Rustgi VK, Park SY, Dunn SL, Schwarz EB. Screening and evaluation of hepatitis C virus infection in pregnant women on opioid maintenance therapy: A retrospective cohort study. Subst Abuse 2016;37:88-95.
3. Patrick SW, Schumacher RE, Benneyworth BD, Krans EE, McAllister JM, Davis MM. Neonatal abstinence syndrome and associated health care expenditures: United States, 2000-2009. JAMA 2012;307:1934-40.
4. Patrick SW, Davis MM, Lehmann CU, Cooper WO. Increasing incidence and geographic distribution of neonatal abstinence syndrome: United States 2009 to 2012. J Perinatol 2015;35: 650-5.
5. Tolia VN, Patrick SW, Bennett MM, Murthy K, Sousa J, Smith PB, et al. Increasing incidence of the neonatal abstinence syndrome in U.S. neonatal ICUs. N Engl J Med 2015;372: 2118-26.
6. Patrick SW, Dudley J, Martin PR, Harrell FE, Warren MD, Hartmann KE, et al. Prescription opioid epidemic and infant outcomes. Pediatrics 2015;135:842-50.
7. Kremer ME, Arora KS. Clinical, Ethical, and Legal Considerations in Pregnant Women With Opioid Abuse. Obstet Gynecol 2015;126:474-8.
8. Public Chapter No. 820, S. 1391, 108th General Assembly, State of Tennessee (2014).
9. The Guttmacher Institute. Substance abuse during pregnancy. State policies in brief. 2015. Available at: http://www.guttmacher. org/statecenter/spibs/spib-SADP.pdf. Retrieved January 7, 2016.
10. Opioid abuse, dependence, and addiction in pregnancy. Committee Opinion No. 524. American College of Obstetricians and Gynecologists. Obstet Gynecol 2012;119:1070-6.
11. NIDA. Drugs, brains and behavior: the science of addiction. Bethesda (MD): National Institutes of Health, National Institute on Drug Abuse; 2010.
12. McLellan AT, Lewis DC, O'Brien CP, Kleber HD. Drug dependence, a chronic medical illness: implications for treatment, insurance, and outcomes evaluation. JAMA 2000;284: 1689-95.
13. American Psychiatric Association. Diagnostic and statistical manual of mental disorders FED. Arlington (VA): American Psychiatric Association; 2013.
14. Dashe JS, Jackson GL, Olscher DA, Zane EH, Wendel Jr. G.D. Opioid detoxification in pregnancy. Obstet Gynecol 1998;92: 854-8.
15. Stewart RD, Nelson DB, Adhikari EH, McIntire DD, Roberts SW, Dashe JS, et al. The obstetrical and neonatal impact of maternal opioid detoxification in pregnancy. Am J Obstet Gynecol 2013;209:267.e1-5.
16. Jones HE, Finnegan LP, Kaltenbach K. Methadone and buprenorphine for the management of opioid dependence in pregnancy. Drugs 2012;72:747-57.
17. Jones HE, Deppen K, Hudak ML, Leffert L, McClelland C, Sahin L, et al. Clinical care for opioid-using pregnant and postpartum women: the role of obstetric providers. Am J Obstet Gynecol 2014;210:302-10.
18. Substance Abuse and Mental Health Services Administration. Medicaid coverage and financing of medications to treat alcohol and opioid use disorders. HHS Publication No. SMA-14-4854. Rockville (MD): Substance Abuse and Metnal Health Services Administration; 2014.
19. U.S. Department of Health and Human Services, National Institutes of Health. Effective medical treatment of opiate addiction. NIH Consens Statement 1997;15:1-38.
20. Methadone.US. Available at: http://www.methadone.us/. Retrieved January 7, 2016.
21. Substance Abuse and Mental Health Services Administration (SAMHSA).Medication-Assisted treatment. Physician and program data. Available at: http://www.samhsa.gov/programs-campaigns/medication-Assisted-Treatment/physician-program-data. Retrieved January 7, 2015.
22. Fiellin DA, Kleber H, Trumble-Hejduk JG, McLellan AT, Kosten TR. Consensus statement on office-based treatment of opioid dependence using buprenorphine. J Subst Abuse Treat 2004;27:153-9.
23. Barry DT, Irwin KS, Jones ES, Becker WC, Tetrault JM, Sullivan LE, et al. Integrating buprenorphine treatment into office-based practice: a qualitative study. J Gen Intern Med 2009;24:218-25.
24. Metz V, Jagsch R, Ebner N, Wurzl J, Pribasnig A, Aschauer C, et al. Impact of treatment approach on maternal and neonatal outcome in pregnant opioid-maintained women. Hum Psychopharmacol 2011;26:412-21.
25. Kakko J, Heilig M, Sarman I. Buprenorphine and methadone treatment of opiate dependence during pregnancy: comparison of fetal growth and neonatal outcomes in two consecutive case series. Drug Alcohol Depend 2008; 96:69-78.
26. Fischer G, Ortner R, Rohrmeister K, Jagsch R, Baewert A, Langer M, et al. Methadone versus buprenorphine in pregnant addicts: a double-blind, double-dummy comparison study. Addiction 2006;101:275-81.
27. Lacroix I, Berrebi A, Garipuy D, Schmitt L, Hammou Y, Chaumerliac C, et al. Buprenorphine versus methadone in pregnant opioid-dependent women: a prospective multicenter study. Eur J Clin Pharmacol 2011;67:1053-9.
28. Jones HE, Kaltenbach K, Heil SH, Stine SM, Coyle MG, Arria AM, et al. Neonatal abstinence syndrome after methadone or buprenorphine exposure. N Engl J Med 2010;363: 2320-31.
29. Zarkin GA, Dunlap LJ, Hicks KA, Mamo D. Benefits and costs of methadone treatment: results from a lifetime simulation model. Health Econ 2005;14:1133-50.
30. Bandstra ES. Maternal Opioid Treatment: Human Experimental Research (MOTHER) Study: maternal, fetal and neonatal outcomes from secondary analyses. Addiction 2012;107 (suppl 1):1-4.
31. Jones ES, Fiellin DA. Women and opioid dependence treatment: office-based versus opioid treatment program-based care? Subst Abuse 2007;28:3-8.
32. Mattick RP, Kimber J, Breen C, Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. The Cochrane Database of Systematic Reviews 2008, Issue 2. Art. No.: CD002207. DOI: 10.1002/14651858.CD002207.pub4.
33. Fischer G, Gombas W, Eder H, Jagsch R, Peternell A, Stuhlinger G, et al. Buprenorphine versus methadone maintenance for the treatment of opioid dependence. Addiction 1999; 94:1337-47.
34. Teruya C, Schwartz RP, Mitchell SG, Hasson AL, Thomas C, Buoncristiani SH, et al. Patient perspectives on buprenorphine/naloxone: a qualitative study of retention during the starting treatment with agonist replacement therapies (START) study. J Psychoactive Drugs 2014;46:412-26.
35. Potter JS, Marino EN, Hillhouse MP, Nielsen S, Wiest K, Canamar CP, et al. Buprenorphine/naloxone and methadone maintenance treatment outcomes for opioid analgesic, heroin, and combined users: findings fromstarting treatment with agonist replacement therapies (START). J Stud Alcohol Drugs 2013;74: 605-13.
36. Patrick SW, Kaplan HC, Passarella M, Davis MM, Lorch SA. Variation in treatment of neonatal abstinence syndrome in US children's hospitals, 2004-2011. J Perinatol 2014;34:867-72.
37. Hudak ML, Tan RC; Committee on Drugs; Committee on Fetus and Newborn; American Academy of Pediatrics. Neonatal drug withdrawal. Pediatrics 2012;129:e540-60.
38. Hall ES, Wexelblatt SL, Crowley M, Grow JL, Jasin LR, Klebanoff MA, et al. A multicenter cohort study of treatments and hospital outcomes in neonatal abstinence syndrome. Pediatrics 2014;134:e527-34.
39. Prenatal drug use and newborn health: federal efforts need better coordination and planning. Washington, DC: U.S. Government Accountability Office; 2015.
40. South AP, Wessel JJ, Sberna A, Patel M, Morrow AL. Hospital readmission among infants with gastroschisis. J Perinatol 2011; 31:546-50.
41. White House Office of National Drug Control Policy. Epidemic: responding to America's prescription drug abuse crisis. Available at: https://www.whitehouse.gov/sites/default/files/ondcp/policyand-research/rx-Abuse-plan.pdf. Retrieved January 7, 2016.
42. Substance Abuse and Mental Health Services Administration, National Center on Substance Abuse and Child Welfare. Available at: https://ncsacw.samhsa.gov/Default.aspx. Retrieved January 7, 2016.
43. U.S. Government Accountability Office. Prenatal drug use and newborn health: federal efforts need better planning and coordination. 2015. Available at: http://gao.gov/products/GAO-15-203. Retrieved January 7, 2016.
44. Protecting Our Infants Act of 2015, S. 799, 114th Cong. (2015).